Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sildenafil in Severe PH Caused by COPD
NCT03185364Unknown
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Jun 2017
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of ASP-001 in pulmonary hypertension (PH) (2 arms), sponsored by Chinese Academy of Medical Sciences. Primary endpoints: Pulmonary Artery Pressure at 12 weeks and Pulmonary Vascular Resistance at 12 weeks. Status: unknown.
02
Drugs
ASP-001
03
Conditions
pulmonary hypertension (PH)
Beyond the preview
Go deeper on NCT03185364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03185364.